Picture of Solvonis Therapeutics logo

SVNS Solvonis Therapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

RCS - Solvonis Therapeutic - Initiation of Research Coverage

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nRSZ5618Oa&default-theme=true

RNS Number : 5618O  Solvonis Therapeutics PLC  26 June 2025

REACH - non-regulatory announcement
26 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Initiation of research coverage by Singer Capital Markets

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
is pleased to announce that Singer Capital Markets ("Singers") has today
initiated equity research coverage (the "Initiation Note") on the Company.

The Initiation Note, titled "Psyching up for success", has been authored by
Dr. Karl Keegan, Head of Life Sciences Research at Singers.

The research note is currently available to eligible institutional investors
and will be made publicly available via Singers next week.

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

 

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

 

The Company's programmes address Alcohol Use Disorder (AUD) and Post-Traumatic
Stress Disorder (PTSD)-conditions which the Company estimates affect over 60
million people across the UK, US, and EU4. Its lead asset, SVN‑001, is
currently in Phase 3 for severe AUD in Europe and the UK. SVN‑002 is
preparing for a Phase 2b trial in the US targeting moderate to severe AUD.
Solvonis also has a preclinical PTSD programme, SVN‑SDN‑014, leveraging
novel serotonin, dopamine, and noradrenalin modulators designed to enhance
pro-social behaviour and long-term outcomes.

 

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders.

 

With a capital-efficient model, focused pipeline strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted companies to distribute media only /
non-regulatory news releases into the public domain.  Information required to
be notified under the Market Abuse Regulation or other regulation would be
disseminated as an RNS regulatory announcement and not on Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUNAKRVWUNURR

Recent news on Solvonis Therapeutics

See all news